FUNDAMENTAL AND CLINICAL STUDIES ON SULBACTAM/CEFOPERAZONE IN THE PEDIATRIC FIELD

• Published in: Japanese journal of antibiotics 1984/10/25, Vol.37(10), pp.1831-1845
• Main Authors: IWATA, SATOSHI, SATO, YOSHITAKE, IWASAKI, YUKIO, HAYANO, SHINYA, WAKABAYASHI, RYO, KOJIMA, YOSHIFUMI, AKITA, HIRONOBU, SUNAKAWA, KEISUKE, OIKAWA, TADAO, OSANO, MITSURU
• Format: Article
• Language: Japanese
• Subjects: Age Factors; Bacteria - drug effects; Bacterial Infections - drug therapy; Bacterial Infections - microbiology; beta-Lactamase Inhibitors; Cefoperazone - administration & dosage; Cefoperazone - metabolism; Cefoperazone - pharmacology; Child; Child, Preschool; Drug Combinations; Drug Evaluation; Drug Resistance, Microbial; Female; Humans; Infant; Male; Penicillanic Acid - administration & dosage; Penicillanic Acid - metabolism; Penicillanic Acid - pharmacology; Sulbactam
• ISSN: 0368-2781; 2186-5477
• DOI: 10.11553/antibiotics1968b.37.1831

Fundamental and clinical studies were carried out on sulbactam/cefoperazone (SBT/CPZ) in the field of pediatrics. The following results were obtained: 1. A total of 185 clinical isolates that had been stocked at our department was employed to determine the minimum inhibitory concentrations (MICs) of SBT/CPZ against various bacterial species. SBT/CPZ showed strong antibacterial potency against E. coli, Salmonella, Klebsiella and P. mirabilis, and relatively strong potency against S. marcescens, P. aeruginosa and S. aureus. 2. Antibacterial potency of SBT/CPZ was stronger than that of CPZ alone against E. coli, and it also showed strong activity against strains of Salmonella, S. marcescens and S. aureus, moderately or highly resistant to CPZ. 3. SBT/CPZ was administered by intravenous bolus infusion to pediatric patients to determine the serum concentrations of SBT and CPZ. At a dose of 10mg/kg the mean serum levels of SBT and CPZ were as follows; 17.8 μg/ml, 40.7μg/ml at 15 minutes and 0.3μg/ml, 3.0μg/ml at 6 hours, respectively. The half-lives of SBT and CPZ in the serum were 1.05 hours and 1.76 hours, respectively. Similarly, at a dose of 20mg/kg the mean serum levels of SBT and CPZ were; 31.9μg/ml, 81.0μg/ml at 15 minutes and 0.5μg/ml, 6.1μg/ml at 6 hours, and the half-lives were 1.00 hour and 1.72 hours, respectively. At a dose of 40mg/kg, only 1 case was determined. The serum levels of SBT and CPZ were 34.4μg/ml, 74.8μg/ml at 30 minutes and 0.2μg/ml, 3.7μg/ml at 6 hours, and the half-lives were 0.78 hour and 1.38 hours, respectively. 4. SBT/CPZ was drip-infused intravenously over a period of 1 hour, and the serum concentrations of SBT and CPZ were determined. At the dose of 10mg/kg or 20mg/kg, the peak serum levels of SBT and CPZ were observed at 1 hour or at the end of drip infusion. At a dose of 10mg/kg the mean serum levels of SBT and CPZ were 14.4μg/ml, 33.7μg/ml at 1 hour and 1.4μg/ml, 4.6μg/ml at 7 hours, respectively. The half-lives was 1.86 hours for SBT and 2.23 hours for CPZ, respectively. Similarly at a dose of 20mg/kg, the mean serum levels of SBT and CPZ were, 22.2μg/ml, 34.6μg/ml at 1 hour and 0.5μg/ml, 2.8μg/ml at 7 hours, and the half-lives was 1.17 hours and 1.75 hours, respectively. 5. The urinary recovery rate was determined for the 6 hours period after admistration. The urinary recovery rate were approximately 30-60% for SBT and 10-20% for CPZ. 6. SBT/CPZ was administered to 11 cases with bacterial infections. A good or excellent cl